MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells

详细信息    查看全文

• 作者：Constanza Cortés ; Sara C. Kozma ; Albert Tauler ; Santiago Ambrosio
• 关键词：Neuroblastoma ; MYCN ; SAHA
• 刊名：Cellular Oncology
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：38
• 期：5
• 页码：341-352
• 全文大小：1,660 KB
• 参考文献：1.J.M. Maris, Recent advances in neuroblastoma. N. Eng. J. Med. 362, 2202-211 (2010)CrossRef
  2.A. Bandino, D. Geerts, J. Koster, A.S. Bachmann, Deoxyhypusine synthase (DHPS) inhibitor GC7 induces p21/Rb-mediated inhibition of tumor cell growth and DHPS expression correlates with poor prognosis in neuroblastoma patients. Cell. Oncol. 37, 387-98 (2014)CrossRef
  3.R.A. Ross, J.L. Biedler, B.A. Spengler, A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors. Cancer Lett. 197, 35-9 (2003)CrossRef PubMed
  4.S.L. Cohn, A.D. Pearson, W.B. London, T. Monclair, P.F. Ambros, G.M. Brodeur, A. Faldum, B. Hero, T. Iehara, D. Machin, V. Mosseri, T. Simon, A. Garaventa, V. Castel, K.K. Matthay, The international neuroblastoma risk group (INRG) classification system: an INRG task force report. Int. J. Oncol. 27, 289-97 (2009)
  5.L.J. Valentijn, J. Koster, F. Haneveld, R.A. Aissa, P. van Sluis, M.E. Broekmans, J.J. Molenaar, J. van Nes, R. Versteeg, Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc. Natl. Acad. Sci. U. S. A. 109, 19190-9195 (2012)PubMed Central CrossRef PubMed
  6.T.J. Pugh, O. Morozova, E. Attiyeh, S. Asgharzadeh, J.S. Wei, D. Auclair, S.L. Carter, K. Cibulskis, M. Hanna, A. Kiezun, J. Kim, M.S. Lawrence, L. Lichenstein, A. McKenna, C.S. Pedamallu, A.H. Ramos, E. Shefler, A. Sivachenko, C. Sougnez, C. Stewart, A. Ally, I. Birol, R. Chiu, R.D. Corbett, M. Hirst, S.D. Jackman, B. Kamoh, A.H. Khodabakshi, M. Krzywinski, A. Lo, R.A. Moore, K.L. Mungall, J. Qian, A. Tam, N. Thiessen, Y. Zhao, K.A. Cole, M. Diamond, S.J. Diskin, Y.P. Mosse, A.C. Wood, L. Ji, R. Sposto, T. Badgett, W.B. London, Y. Moyer, J.M. Gastier-Foster, M.A. Smith, J.M. Guidry Auvil, D.S. Gerhard, M.D. Hogarty, S.J. Jones, E.S. Lander, S.B. Gabriel, G. Getz, R.C. Seeger, J. Khan, M.A. Marra, M. Meyerson, J.M. Maris, The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45, 279-84 (2013)PubMed Central CrossRef PubMed
  7.A. Canette, M. Gerrard, H. Rubie, V. Castel, A. Di Cataldo, C. Munzer, R. Ladenstein, B. Brichard, J.D. Bermúdez, J. Couturier, B. de Bernardi, A.J. Pearson, J. Michon, Poor survival for infants with MYCN amplified metastatic neuroblastoma despite intensified treatment: the international society of paediatric oncology european neuroblastoma experience. J. Clin. Oncol. 27, 1014-019 (2009)CrossRef
  8.S. Gherardi, E. Valli, D. Erriquez, G. Perini, MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin. Front. Oncol. 3, 1- (2013)CrossRef
  9.P.J. Hurlin, N-myc functions in transcription and development. Birth Defects Res. 75, 340-52 (2005)CrossRef
  10.M. Huang, W.A. Weiss, Neuroblastoma and MYCN. Cold Spring Harbour Perspect. Med. (2013). doi:10.-101/?cshperspect.?a014415
  11.E. Bell, L. Chen, T. Liu, G.M. Marshall, J. Lunec, D.A. Tweddle, MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 293, 144-57 (2010)CrossRef PubMed
  12.T.P. Stricker, A. Morales, A. Chlenski, L. Guerrero, H.R. Salwen, Y. Gosiengfiao, E.J. Perlman, W. Furman, A. Bahrami, J.M. Shohet, P.E. Zage, M.J. Hicks, H. Shimada, R. Suganuma, J.R. Park, S. So, W.B. London, P. Pytel, K.H. Maclean, S.L. Cohn, Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounterTM system. Mol. Oncol. (2014). doi:10.-016/?j.?molonc.-014.-1.-1 PubMed Central PubMed
  13.S.R. Frank, T. Parisi, S. Taubert, P. Fernandez, M. Fuchs, H.M. Chan, D.M. Livingston, B. Amati, MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep. 4, 575-80 (2003)PubMed Central CrossRef PubMed
  14.R. Francisco, A. Pérez-Perarnau, C. Cortés, J. Gil, A. Tauler, S. Ambrosio, Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. Cancer Lett. 318, 42-2 (2012)CrossRef PubMed
  15.F.A. Duijkers, R.X. de Menezes, I.J. Goossens-Beumer, D.J. Stumpel, P. Admiraal, R. Pieters, J.P. Meijerink, M.M. van Noesel, Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines. Cell. Oncol. 36, 351-62 (2013)CrossRef
  16.O. Witt, H.E. Deubzer, M. Lodrini, T. Milde, I. Oehme, Targeting histone deacetylases in neuroblastoma. Curr. Pharm. Des. 15, 436-47 (2009)CrossRef PubMed
  17.D.C. Coffey, M.C. Kutko, R.D. Glick, L.M. Butler, G. Heller, R.A. Rifkind, P.A. Marks, V.M. Richon, M.P. La Quaglia, The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 61, 3591-594 (2001)PubMed
  18.P.A. Marks, W.S. Xu, Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. 107, 600-08 (2009)PubMed Central CrossRef PubMed
  19.M. Fouladi, J.R. Park, C.F. Stewart, R.J. Gilbertson, P. Schaiquevich,
• 作者单位：Constanza Cortés (1) (2)
  Sara C. Kozma (2)
  Albert Tauler (1) (2)
  Santiago Ambrosio (3)
  
  1. Departament de Bioquímica i Biologia Molecular, Facultat de Farmàcia, Universitat de Barcelona, 08028, Barcelona, Catalunya, Spain
  2. Laboratory of Cancer Metabolism, IDIBELL, Hospital Duran i Reynals, L’Hospitalet de Llobregat, Catalunya, 08907, Spain
  3. Unitat de Bioquímica, Dep. Ciències Fisiològiques II, Facultat de Medicina, Campus Universitari de Bellvitge - IDIBELL, Universitat de Barcelona, L’Hospitalet de Llobregat, Catalunya, 08907, Spain
  
• 刊物主题：Cancer Research; Biomedicine general; Pathology; Oncology;
• 出版者：Springer Netherlands
• ISSN：2211-3436

文摘

Background In the past, the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) has been shown to induce apoptosis in several human tumor types, including neuroblastomas. Amplification and over-expression of the MYCN oncogene is a diagnostic hallmark and a poor prognostic indicator in high-risk neuroblastomas. Here, we studied the relationship between MYCN amplification and over-expression and the anti-tumor effect of SAHA to assess whether this drug may serve as a treatment option for high-risk neuroblastomas.